On April 9, Pfizer said it found promising results for Abrysvo, its RSV vaccine the FDA approved in May 2023 for adults 60 and older. Abrysvo was well-tolerated and safe in a phase 3 study of adults aged between 18 and 49, the drugmaker said, adding that co-primary immunogenicity endpoints and primary safety endpoints were met in the trial.
Pfizer did not quantify the efficacy results, but the company said it plans to seek regulatory approval for the age group.
The other approved RSV vaccine, GSK’s Arexvy, is indicated for patients 60 and older.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
